The Life Sciences team advised California-based BridgeBio Pharma, Inc. (Nasdaq: BBIO) and its affiliate QED Therapeutics, Inc. on a global collaboration and licensing agreement with Helsinn Group to further develop and commercialize QED Therapeutics’ FGFR1-3 inhibitor, infigratinib, in oncology and all other indications except for skeletal dysplasias (including achondroplasia).
Under the terms of the agreement, QED and Helsinn will co-commercialize infigratinib in oncology indications in the U.S. Helsinn will have exclusive commercialization rights and lead commercialization for infigratinib in non-skeletal dysplasia indications outside of the U.S., excluding Greater China.
Under the terms of the agreement, QED is eligible to receive payments totaling up to approximately $2.45 billion in the aggregate, including over $100 million in upfront, regulatory and launch milestone payments, and the remainder subject to the achievement of specified commercial milestones, as well as tiered royalties on adjusted net sales from the Helsinn Group on licensed products sold worldwide, outside of the United States and Greater China. In addition, QED and HTU will co-commercialize infigratinib in the licensed indications in the U.S. and will equally share profits and losses.
BridgeBio is a biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers. BridgeBio affiliate QED Therapeutics is a biotechnology company focused on precision medicine for FGFR-driven diseases.
Helsinn Group is a privately-owned Swiss Pharma Company.
The Goodwin team was led by Noelle Dubiansky and Emily Beman, and included Alexandra Haas, Maggie Wong, Theresa Kavanaugh, Michael Brodowski, Jessica Rothstein, Paul Jin, Dan Karelitz, Nicole Spiteri, and William Weintraub.
For additional details, please read the press release and articles in Endpoints, BioWorld, and Precision Oncology News.